Annette von Delft
Annette trained as a medical doctor at University of Leipzig (Germany) and received her D.Phil in Clinical Medicine at the University of Oxford in 2010. Her project focused on HCV T cell immunology and vaccine development under the supervision of Prof Eleanor Barnes. She then completed her medical foundation programme at Oxford University Hospitals.
Annette joined the BRC team in 2018 as a translational scientist with a focus on inflammation and immunity. She is currently involved in a range of projects in immunology, infectious disease and neuroscience.
Accelerating antiviral drug discovery: lessons from COVID-19.
von Delft A. et al, (2023), Nat Rev Drug Discov
Open Science Discovery of Potent Non-Covalent SARS-CoV-2 Main Protease Inhibitors
Achdout H. et al, (2020)
MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans.
Esposito I. et al, (2020), Sci Transl Med, 12
The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.
von Delft A. et al, (2018), Vaccine, 36, 313 - 321
Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus.
Ansari MA. et al, (2017), Nat Genet, 49, 666 - 673